[Research progress of cementless prosthesis in total knee arthroplasty]. [PDF]
Tai W, Qi X, Wang B, Chai W.
europepmc +1 more source
由于CO甲烷化的快速表面反应、强放热特性,相比固定床,采用小颗粒催化剂的流化床甲烷化技术在反应活性和催化剂稳定性方面具有明显的技术优势。从高耐磨催化剂、流化床反应器及其创新、短流程两段甲烷化技术构建及其验证等方面总结了流化床甲烷化技术开发的最新进展。优化催化剂前体制备方法、调变催化剂组成可获得具有较高骨架强度和均匀性的催化剂一次微粒,进而通过优化的喷雾造粒工艺和填充黏结剂,制备出具有可调变粒度分布、高强度和高球形度的流化床用粉末催化剂,但其黏结剂的添加明显影响催化剂的低温活性 ...
许光文 +7 more
core
[Staged comprehensive limb reconstruction strategy and effectiveness analysis for severe open lower leg injury]. [PDF]
Yin L +11 more
europepmc +1 more source
[Expert consensus on clinical pathway for high-conformity total knee arthroplasty through a minimally invasive surgical approach]. [PDF]
Expert Consensus Development Group On Clinical Pathways For High-Conformity Total Knee Arthroplasty Through A Minimally Invasive Surgical Approach +1 more
europepmc +1 more source
[Transcutaneous osseointegration for amputees: foundational principles and current concepts]. [PDF]
Jason S H +3 more
europepmc +1 more source
[Classification and Ilizarov reconstruction strategies for post-infectious calcaneal bone defects]. [PDF]
Cheng X +7 more
europepmc +1 more source
采用响应面分析法对影响粘红酵母细胞固定化的4个主要因素——单体浓度、交联剂浓度、包埋量、包埋时间进行了优化.首先用Plackett-Burman法设计实验对以上4个影响因素进行了评价,并筛选出显著影响因素——单体浓度和包埋量;第2步用最陡爬坡实验逼近以上两因素最优水平;最后由中心复合实验及响应面分析确定主要影响因素的最佳条件.固定化粘红酵母细胞的最优包埋条件为:单体浓度16.7%,包埋量43%,交联剂浓度2.0%,包埋时间45min.在此条件下得到的固定化细胞与游离细胞相比,酶活保留率可达63 ...
李铭, 杨顺楷, 杨亚力
core
[Expert consensus on clinical pathway of high-conformity total knee arthroplasty under the enhanced recovery after surgery protocol]. [PDF]
Expert Consensus Development Group On Clinical Pathways For High-Conformity Total Knee Arthroplasty Under The Enhanced Recovery After Surgery Protocols +1 more
europepmc +1 more source
[Efficient dental panoramic radiographic diagnosis under resource constraints <i>via</i> edge quantization and multi-modal synergy]. [PDF]
Zhao T +6 more
europepmc +1 more source
[Effectiveness analysis of anterior intervertebral osteotomy and fusion assisted by inflection point of uncinate process for treatment of cervical spondylotic myelopathy]. [PDF]
Hu Y +5 more
europepmc +1 more source

